Cost Utility of Vaccination Against COVID-19 in Brazil

Fernandes, Ricardo; Santos, Marisa; Magliano, Carlos Alberto da Silva; Tura, Bernardo Rangel; Macedo, Luana Schroeder Damico Nascimento; Padila, Matheus Piccin; França, Ana Cláudia Wekmuller; Braga, Andressa Araujo

doi:10.1016/j.vhri.2022.01.009

Cited by 15 publications

(50 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two remaining studies were conducted in multiple countries; the first one comprised four analyses from LMICs and two analyses from HICs [ 36 ], while the other study comprised 12 analyses in LMICs [ 42 ]. Sixteen studies were conducted in 2021 [ 21 - 28 , 30 - 33 , 35 - 37 , 41 ], while nine studies were conducted in 2022 [ 29 , 34 , 38 - 40 , 42 - 45 ]. Most of the included studies (21/25) aimed to estimating the economic evaluation of different vaccination strategies [ 21 - 30 , 32 , 33 , 35 - 38 , 40 , 42 - 45 ], while two studies were conducted with the goal of estimating the economic evaluation of vaccination vs no vaccination [ 34 , 41 ].…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, three studies presented a range of two to three categories of vaccination coverage each [ 25 , 32 , 42 ]. Eight studies, however, did not report on vaccination coverage [ 23 , 24 , 28 , 29 , 31 , 38 , 39 , 43 ].…”

Section: Resultsmentioning

confidence: 99%

“…Each analysis used a different evaluation to determine whether the use of vaccinations was considered cost-effective, e.g. by considering the procurement of the vaccine program compared with the absence of a vaccination program [ 21 , 26 , 33 , 36 , 39 , 41 , 45 , 48 , 50 ], the coverage of the vaccine used [ 37 , 40 , 42 , 49 ], the existence of priority vaccines for specific populations [ 25 , 30 , 33 , 34 , 38 , 41 ], the efficacy of many vaccines on the market [ 23 , 24 , 29 , 35 , 41 , 43 ], and the provision of boosters following vaccination [ 34 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Economic evaluation of COVID-19 vaccination: A systematic review

et al. 2023

View full text Add to dashboard Cite

Background Safe and effective vaccination is considered to be the most critical strategy to fight coronavirus disease 2019 (COVID-19), leading to individual and herd immunity protection. We aimed to systematically review the economic evaluation of COVID-19 vaccination globally. Methods We performed a systematic search to identify relevant studies in two major databases (MEDLINE/PubMed and EBSCO) published until September 8, 2022. After deduplication, two researchers independently screened the study titles and abstracts according to pre-determined inclusion and exclusion criteria. The remaining full-text studies were assessed for eligibility. We assessed their quality of reporting using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist and summarized and narratively presented the results. Results We identified 25 studies that assessed the economic evaluation of COVID-19 vaccination worldwide by considering several input parameters, including vaccine cost, vaccine efficacy, utility value, and the size of the targeted population. All studies suggested that COVID-19 vaccination was a cost-effective or cost-saving intervention for mitigating coronavirus transmission and its effect in many countries within certain conditions. Most studies reported vaccine efficacy values ranging from 65% to 75%. Conclusions Given the favorable cost-effectiveness profile of COVID-19 vaccines and disparities in affordability across countries, considering prioritization has become paramount. This review provides comprehensive insights into the economic evaluation of COVID-19 vaccination that will be useful to policymakers, particularly in highlighting preventive measures and preparedness plans for the next possible pandemic.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Economic evaluation of COVID-19 vaccination: A systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…They state that the vaccination campaign during 2021 was cost-saving in all the countries analyzed. In addition, Fernandes et al 13 published a cost-utility analysis of three Covid-19 vaccines in Brazil. They reported cost-saving results for two of the three most common vaccines in that country (Oxford and Janssen vaccine).…”

Section: Discussionmentioning

confidence: 99%

“…Vaccination for the recent SARS-CoV-2 pandemic has generally been implemented without formally assessing this dimension, given the global emergency it caused. More recently, several cost-effectiveness analyses of COVID-19 vaccination have been published [4][5][6][7][8][9][10][11][12] , most of them focused on high-income countries and only one with a speci c focus on a Latin American country 13 .…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness of COVID-19 Vaccination in Latin America and the Caribbean: An Analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru

et al. 2022

View full text Add to dashboard Cite

Economic evaluation of vaccination against COVID‐19: A systematic review

Zeinab,

Shahin,

Fateme

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsCoronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic review to provide economic evidence of the value of different types of vaccines available to combat the Covid‐19 to all health policymakers worldwide.MethodsElectronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as “Vaccination,” “Covid‐19,” “Cost‐benefit,” “Cost‐utility,” “Cost‐effectiveness,” “Economic Assessment,” and “Economic evaluation.” Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the review.ResultsAll messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer's perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost‐effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost‐benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered.ConclusionThe COVID‐19 primary vaccination programs in regional outbreaks, from a long‐term perspective, will demonstrate substantial cost‐effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX‐19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world.

show abstract

Cost Utility of Vaccination Against COVID-19 in Brazil

Cited by 15 publications

References 14 publications

Economic evaluation of COVID-19 vaccination: A systematic review

Economic evaluation of COVID-19 vaccination: A systematic review

Cost-Effectiveness of COVID-19 Vaccination in Latin America and the Caribbean: An Analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru

Economic evaluation of vaccination against COVID‐19: A systematic review

Contact Info

Product

Resources

About